Comparison of Non-Tumoral Portal Vein Thrombosis Management in Cirrhotic Patients: TIPS Versus Anticoagulation Versus No Treatment

• Main Authors: Chenyang Zhan, Vinay Prabhu, Stella K. Kang, Clayton Li, Yuli Zhu, Sooah Kim, Sonja Olsen, Ira M. Jacobson, Nabil N. Dagher, Brendan Carney, Ryan M. Hickey, Bedros Taslakian
• Format: Article
• Language: English
• Published: MDPI AG 2021-05-01
• Series: Journal of Clinical Medicine
• Subjects: non-tumoral portal vein thrombosis; transjugular intrahepatic portosystemic shunt; anticoagulation
• Online Access: https://www.mdpi.com/2077-0383/10/11/2316

Background: There is a lack of consensus in optimal management of portal vein thrombosis (PVT) in patients with cirrhosis. The purpose of this study is to compare the safety and thrombosis burden change for cirrhotic patients with non-tumoral PVT managed by transjugular intrahepatic portosystemic shunt (TIPS) only, anticoagulation only, or no treatment. Methods: This single-center retrospective study evaluated 52 patients with cirrhosis and non-tumoral PVT managed by TIPS only (14), anticoagulation only (11), or no treatment (27). The demographic, clinical, and imaging data for patients were collected. The portomesenteric thrombosis burden and liver function tests at early follow-up (6–9 months) and late follow-up (9–16 months) were compared to the baseline. Adverse events including bleeding and encephalopathy were recorded. Results: The overall portomesenteric thrombosis burden improved in eight (72%) TIPS patients, three (27%) anticoagulated patients, and two (10%) untreated patients at early follow-up (<i>p</i> = 0.001) and in seven (78%) TIPS patients, two (29%) anticoagulated patients, and three (17%) untreated patients in late follow-up (<i>p</i> = 0.007). No bleeding complications attributable to anticoagulation were observed. Conclusion: TIPS decreased portomesenteric thrombus burden compared to anticoagulation or no treatment for cirrhotic patients with PVT. Both TIPS and anticoagulation were safe therapies.